Brain activity linked to motor and psychiatric ups and downs in Parkinson's

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Swiss prospective observational study will record resting-state high-density EEG together with subthalamic nucleus (STN) local field potentials (LFPs) in about 30 Parkinson's patients with recently implanted STN‑DBS systems during a modified levodopa challenge. Recordings use chronic-capable DBS hardware to capture cortical-subcortical oscillatory activity across beta, alpha, and gamma bands 4–8 weeks post-implant. The protocol compares electrophysiological signatures across motor and neuropsychiatric fluctuation states to identify frequency-specific correlates. Results will map cortical‑STN interactions associated with acute dopaminergic changes and symptomatic ups and downs.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of Parkinson's disease (PD) based on United Kingdom Parkinson's Disease Society Brain Bank Criteria.
* Patients candidate for STN-DBS in the PD phase called fluctuations stage.
* Presence of fluctuations (motor and/or non-motor) are based on the pre-surgical DBS assessment:
* To be on dopaminergic therapy.
* Patients who have undergone STN-DBS implantation within 4 to 8 weeks before electrophysiological acquisition.

Exclusion Criteria:

* Patients with an age greater than 80 years,
* Dementia (defined by a MOCA score ≤24),
* Active psychosis or depression with suicidal ideation,
* Any clinically meaningful non-stable physical diseases,
* Patients with OFF-drug state so severe that it prevents study tests from being carried out (e.g acute painful dystonia, intolerable non-motor symptoms such as pain, anxiety),
* Participating in a pharmacological study,
* Inability to provide informed consent (legal guardianship).

Where it's running

• Geneva University Hospital
  Geneva, Switzerland Recruiting

Study contacts

• Study coordinator: Damien BENIS, PhD
• Email: damien.benis@hug.ch
• Phone: +41223722311

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• UX-DA003 injections for Parkinson's disease

  This early-phase trial tests whether injecting UX-DA003 is safe and may help motor symptoms in people with Parkinson's whose response to standard treatments has declined.

  Recruiting Early Phase 1 The First Affiliated Hospital of Anhui Medical University · Hefei, Anhui · NCT07911670

• Strength and dual-task training to help people with Parkinson’s improve strength and function

  This trial tests three levels of physiotherapy, including progressive resistance training with and without cognitive dual-task and instability components, to see if they improve muscle strength, body composition, and physical function in adults with Parkinson’s or related syndromes.

  Recruiting University of Valencia · Valencia, Valencia · NCT07907302

• Spinal Mobility, Rigidity, and Kinesiophobia in Parkinson's Disease with and without TMD

  This study tests whether people with Parkinson's disease who have Temporomandibular Disorders differ in spinal mobility, axial rigidity, and kinesiophobia from those without TMD.

  Recruiting Mustafa Kemal University · Hatay · NCT07850674

• A 12-Week Trial of Flexilev with the OraFID Device and App for Parkinson's

  This study tests whether taking small, precise doses of Flexilev with the OraFID dosing device and Levilog app is acceptable and helps people with Parkinson's manage their medicine.

  Recruiting at 2 sites Phase 4 Navamedic AB · Stockholm, Stockholm County and 4 other locations · NCT07839793

• Integrated Motor-Cognitive Training in Parkinson's Disease

  This study tests a combined motor and cognitive rehabilitation program to see if people with Parkinson’s disease can stick with it and show early signs of benefit.

  Recruiting University Hospital of Ferrara · Ferrara, FE · NCT07833748

• VIM0423 for Parkinson's Tremor in Adults Not Fully Controlled by Dopaminergic Therapy

  A Vima Therapeutics study tests whether the oral drug VIM0423 can reduce tremor in adults with Parkinson’s disease who still have tremor despite dopaminergic treatment.

  Recruiting at 4 sites Phase 2 Vima Therapeutics · Scottsdale, Arizona and 29 other locations · NCT07804615

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.